EP 1261369 A2 20021204 - COMPOSITIONS AND METHODS FOR TUMOR-TARGETED DELIVERY OF EFFECTOR MOLECULES
Title (en)
COMPOSITIONS AND METHODS FOR TUMOR-TARGETED DELIVERY OF EFFECTOR MOLECULES
Title (de)
VERBINDUNGEN UND METHODEN ZUM TUMORGERICHTETEN TRANSPORT VON EFFEKTORMOLEKÜLEN
Title (fr)
COMPOSITIONS ET METHODES D'ADMINISTRATION DE MOLECULES EFFECTRICES CIBLEES SUR LES TUMEURS
Publication
Application
Priority
- US 0023242 W 20000824
- US 15750099 P 19991004
- US 15758199 P 19991004
- US 15763799 P 19991004
Abstract (en)
[origin: WO0125397A2] The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
IPC 1-7
IPC 8 full level
A61K 35/74 (2006.01); A61K 38/00 (2006.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/39 (2006.01); A61K 38/43 (2006.01); A61K 38/46 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07K 7/06 (2006.01); C07K 14/035 (2006.01); C07K 14/16 (2006.01); C07K 14/225 (2006.01); C07K 14/50 (2006.01); C07K 19/00 (2006.01); C12N 1/21 (2006.01); C12N 1/36 (2006.01); C12N 15/09 (2006.01); C12N 15/62 (2006.01); C12N 15/74 (2006.01)
CPC (source: EP KR)
A61K 35/74 (2013.01 - EP); A61K 38/162 (2013.01 - EP); A61K 38/164 (2013.01 - EP); A61K 38/177 (2013.01 - EP); A61K 38/191 (2013.01 - EP); A61K 38/195 (2013.01 - EP); A61K 38/39 (2013.01 - EP); A61K 38/51 (2013.01 - EP); A61K 45/06 (2013.01 - EP); A61K 48/0008 (2013.01 - EP); A61P 35/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C12N 1/20 (2013.01 - KR); C12N 15/62 (2013.01 - EP); C12N 15/625 (2013.01 - EP); C12N 15/74 (2013.01 - EP); C07K 2319/01 (2013.01 - EP); C07K 2319/035 (2013.01 - EP); Y02A 50/30 (2017.12 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0125397 A2 20010412; WO 0125397 A3 20020124; AU 6933400 A 20010510; AU 783714 B2 20051201; BR 0014491 A 20040309; CA 2386465 A1 20010412; CN 1420783 A 20030528; EP 1261369 A2 20021204; EP 1261369 A4 20060201; IL 148933 A0 20020912; JP 2004500042 A 20040108; KR 20020059605 A 20020713; MX PA02003384 A 20020820; NZ 518354 A 20050225
DOCDB simple family (application)
US 0023242 W 20000824; AU 6933400 A 20000824; BR 0014491 A 20000824; CA 2386465 A 20000824; CN 00816714 A 20000824; EP 00957764 A 20000824; IL 14893300 A 20000824; JP 2001528552 A 20000824; KR 20027004371 A 20020404; MX PA02003384 A 20000824; NZ 51835400 A 20000824